Dolby Laboratories, Inc. (NYSE:DLB) Major Shareholder Sells $1,434,926.38 in Stock

Dolby Laboratories, Inc. (NYSE:DLB) major shareholder Dagmar Dolby sold 22,069 shares of the firm’s stock in a transaction on Friday, July 12th. The stock was sold at an average price of $65.02, for a total value of $1,434,926.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Dagmar Dolby also recently made the following trade(s):

  • On Wednesday, July 17th, Dagmar Dolby sold 100,000 shares of Dolby Laboratories stock. The stock was sold at an average price of $65.27, for a total value of $6,527,000.00.
  • On Monday, July 15th, Dagmar Dolby sold 72,069 shares of Dolby Laboratories stock. The stock was sold at an average price of $65.10, for a total value of $4,691,691.90.
  • On Friday, July 5th, Dagmar Dolby sold 26,358 shares of Dolby Laboratories stock. The stock was sold at an average price of $65.01, for a total value of $1,713,533.58.
  • On Wednesday, July 3rd, Dagmar Dolby sold 77,692 shares of Dolby Laboratories stock. The stock was sold at an average price of $65.17, for a total value of $5,063,187.64.
  • On Monday, July 1st, Dagmar Dolby sold 50,000 shares of Dolby Laboratories stock. The stock was sold at an average price of $65.06, for a total value of $3,253,000.00.
  • On Thursday, June 27th, Dagmar Dolby sold 51,777 shares of Dolby Laboratories stock. The stock was sold at an average price of $65.06, for a total value of $3,368,611.62.
  • On Tuesday, June 25th, Dagmar Dolby sold 15,617 shares of Dolby Laboratories stock. The stock was sold at an average price of $65.04, for a total value of $1,015,729.68.
  • On Friday, June 21st, Dagmar Dolby sold 93,113 shares of Dolby Laboratories stock. The stock was sold at an average price of $65.11, for a total value of $6,062,587.43.
  • On Wednesday, May 15th, Dagmar Dolby sold 50,000 shares of Dolby Laboratories stock. The stock was sold at an average price of $65.05, for a total value of $3,252,500.00.
  • On Wednesday, May 8th, Dagmar Dolby sold 46,781 shares of Dolby Laboratories stock. The stock was sold at an average price of $65.12, for a total value of $3,046,378.72.

Shares of NYSE:DLB opened at $65.11 on Friday. The business’s 50-day simple moving average is $63.87. The firm has a market cap of $6.64 billion, a P/E ratio of 27.13, a price-to-earnings-growth ratio of 2.11 and a beta of 0.82. Dolby Laboratories, Inc. has a 12-month low of $58.17 and a 12-month high of $72.04.

Dolby Laboratories (NYSE:DLB) last issued its quarterly earnings data on Wednesday, May 1st. The electronics maker reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.52 by $0.18. The firm had revenue of $338.26 million during the quarter, compared to the consensus estimate of $337.45 million. Dolby Laboratories had a return on equity of 11.12% and a net margin of 24.93%. The company’s quarterly revenue was up 12.9% on a year-over-year basis. During the same period last year, the company earned $0.73 EPS. Equities analysts predict that Dolby Laboratories, Inc. will post 2.38 earnings per share for the current fiscal year.

A number of analysts recently issued reports on the company. B. Riley set a $18.00 price objective on TiVo and gave the stock a “buy” rating in a research report on Thursday, June 13th. ValuEngine raised Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, April 1st. Finally, Zacks Investment Research downgraded Inflarx from a “buy” rating to a “hold” rating in a research report on Friday, May 3rd. Two equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $76.50.

Large investors have recently modified their holdings of the stock. Penserra Capital Management LLC boosted its stake in shares of Dolby Laboratories by 50.0% in the 1st quarter. Penserra Capital Management LLC now owns 669 shares of the electronics maker’s stock valued at $42,000 after buying an additional 223 shares during the period. NumerixS Investment Technologies Inc purchased a new position in shares of Dolby Laboratories in the 4th quarter valued at about $43,000. Advisory Alpha LLC purchased a new position in shares of Dolby Laboratories in the 1st quarter valued at about $53,000. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Dolby Laboratories by 45.7% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 1,490 shares of the electronics maker’s stock valued at $94,000 after buying an additional 467 shares during the period. Finally, ETF Managers Group LLC boosted its stake in shares of Dolby Laboratories by 8.6% in the 1st quarter. ETF Managers Group LLC now owns 2,264 shares of the electronics maker’s stock valued at $143,000 after buying an additional 179 shares during the period. 56.00% of the stock is owned by hedge funds and other institutional investors.

About Dolby Laboratories

Dolby Laboratories, Inc creates audio and imaging technologies that transform entertainment and communications at the cinema, at home, at work, and on mobile devices. The company develops and licenses its audio technologies, such as AAC & HE-AAC, a digital audio codec solution used for TVs, set-top boxes (STBs), personal computers (PCs), gaming consoles, mobile devices, and digital radio; AVC, a digital video codec with high bandwidth efficiency used in media devices; Dolby AC-4, an audio coding technology that delivers new audio experiences to a range of playback devices; and Dolby Atmos technology for home theaters, cinemas, device speakers, mobile devices, and headphones.

Further Reading: Momentum Indicator: Relative Strength Index

Insider Buying and Selling by Quarter for Dolby Laboratories (NYSE:DLB)

Receive News & Ratings for Dolby Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dolby Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.